Merck: thumbs up from FDA for prostate cancer drug
(CercleFinance.com) - AstraZeneca and Merck have announced that the US FDA has approved Lynparza, in combination with abiraterone and prednisone or prednisolone, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutation (BRCAm).
In the US, prostate cancer is the second most common cancer in men, and despite an increase in the number of treatments available for patients with mCRPC, five-year survival remains poor, the company says.
In addition, around 10% of mCRPC patients will have BRCA mutations, which are associated with a poor prognosis and poorer outcomes.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
In the US, prostate cancer is the second most common cancer in men, and despite an increase in the number of treatments available for patients with mCRPC, five-year survival remains poor, the company says.
In addition, around 10% of mCRPC patients will have BRCA mutations, which are associated with a poor prognosis and poorer outcomes.
Copyright (c) 2023 CercleFinance.com. All rights reserved.